Cerus Reports Strong 2025 Financials, Exceeding $233M Revenue, Narrows Net Loss, Reaffirms 2026 Growth Guidance
Summary
Cerus Corporation announced robust full-year and fourth-quarter 2025 financial results, featuring significant revenue growth, a narrowed net loss, and reaffirmed positive guidance for 2026 product revenue.
Key Events
-
Strong 2025 Revenue Growth
Reported full-year 2025 total revenue of $233.8 million, a 16% increase from 2024, with product revenue growing 14% to $206.1 million.
-
Improved Profitability Metrics
GAAP net loss narrowed to $15.6 million for 2025, and non-GAAP adjusted EBITDA was positive $9.5 million, marking the second consecutive year of positive adjusted EBITDA.
-
Reaffirmed 2026 Guidance
Reaffirmed full-year 2026 product revenue guidance of $224 million to $228 million, representing 9% to 11% year-over-year growth.
-
Strategic Market Expansion
Entered a group purchasing agreement with Blood Centers of America (BCA), significantly expanding access to its licensed product portfolio across approximately 50% of the U.S. blood supply.
Analysis
Cerus Corporation delivered strong financial performance in 2025, marked by a 16% increase in total revenue to $233.8 million and a 14% rise in product revenue to $206.1 million. The company successfully narrowed its GAAP net loss and achieved positive non-GAAP adjusted EBITDA for the second consecutive year, demonstrating improved operational efficiency and financial health. The reaffirmation of 9-11% product revenue growth for 2026, alongside strategic achievements like the BCA group purchasing agreement and the initiation of a Phase 4 clinical study, indicates continued positive momentum and strengthens the company's market position in safeguarding the global blood supply. Investors should note the consistent execution and positive outlook.
At the time of this filing, CERS was trading at $2.53 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $486M. The 52-week trading range was $1.12 to $2.96. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.